Skip to content

Exelixis EXEL EPS (Diluted)

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$8.26+170%
Pfizer logo
PfizerPFE
$0.47-9.6%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$0.24-167%
Incyte logo
IncyteINCY
$1.47+83.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$0.56+39.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's EPS (diluted)?
Exelixis (EXEL) reported EPS (diluted) of $0.79 in Q1 2026.
How has Exelixis's EPS (diluted) changed year-over-year?
Exelixis's EPS (diluted) increased by 43.6% year-over-year, from $0.55 to $0.79.
What is the long-term trend for Exelixis's EPS (diluted)?
Over 3 years (2021 to 2025), Exelixis's EPS (diluted) has grown at a 56.7% compound annual growth rate (CAGR), from $0.72 to $2.77.
What does EPS (diluted) mean?
The profit per share if all potential sources of new shares were converted into actual stock.
How do you interpret EPS (diluted)?
A smaller gap between basic and diluted EPS indicates less potential dilution for existing shareholders.
How does EPS (diluted) compare across companies?
Standardized metric used to assess the impact of equity-based compensation and convertible instruments.